Enwei Pharmaceutical Co., Ltd. (SHE:301331)
China · Delayed Price · Currency is CNY 38.85
+2.31 (6.32%)
Last updated: Aug 25, 2025
Enwei Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2018 - 2020 |
Net Income | 45.38 | 37.5 | 86.31 | 67.8 | 101.73 | 98.74 | Upgrade |
Depreciation & Amortization | 46.13 | 46.13 | 34.83 | 30.91 | 30.5 | 32.79 | Upgrade |
Other Amortization | 6.58 | 6.58 | 6.55 | 6.88 | 5.59 | 4.56 | Upgrade |
Loss (Gain) From Sale of Assets | 0.26 | 0.26 | 0.04 | - | - | - | Upgrade |
Asset Writedown & Restructuring Costs | 5.44 | 5.44 | 0.58 | 1.65 | 0.07 | -0.09 | Upgrade |
Loss (Gain) From Sale of Investments | -3.49 | -3.49 | -3.74 | -0.59 | 0.44 | -0.01 | Upgrade |
Other Operating Activities | 34.57 | 23.84 | 0.35 | -1.56 | -0.52 | 6.18 | Upgrade |
Change in Accounts Receivable | -36.43 | -36.43 | -9.67 | -69.89 | 30.16 | -44.31 | Upgrade |
Change in Inventory | -12.06 | -12.06 | -2.9 | 5.4 | -31.39 | -7.48 | Upgrade |
Change in Accounts Payable | 12.96 | 12.96 | -27.81 | 22.12 | -50.73 | -13.51 | Upgrade |
Operating Cash Flow | 97.53 | 78.92 | 84.01 | 62.35 | 87.58 | 78.52 | Upgrade |
Operating Cash Flow Growth | 8.88% | -6.06% | 34.73% | -28.80% | 11.53% | -34.40% | Upgrade |
Capital Expenditures | -46.27 | -50.23 | -134.05 | -23.56 | -38.21 | -31.16 | Upgrade |
Sale of Property, Plant & Equipment | 0.34 | 0.34 | 0.15 | - | - | 0.01 | Upgrade |
Investment in Securities | -1,018 | -1,018 | -685.5 | -221.5 | - | - | Upgrade |
Other Investing Activities | 946.49 | 957.37 | 775.22 | 1.05 | 0.52 | 0.32 | Upgrade |
Investing Cash Flow | -117.54 | -110.62 | -44.18 | -244.01 | -37.7 | -30.83 | Upgrade |
Long-Term Debt Issued | - | 241.8 | - | - | - | - | Upgrade |
Long-Term Debt Repaid | - | -48.09 | - | - | - | -10 | Upgrade |
Net Debt Issued (Repaid) | 160.71 | 193.71 | - | - | - | -10 | Upgrade |
Issuance of Common Stock | 18.36 | 18.36 | - | 470.75 | - | - | Upgrade |
Repurchase of Common Stock | -70.01 | -70.01 | -33 | - | - | - | Upgrade |
Common Dividends Paid | -56.96 | -56.96 | -112.22 | - | -46 | -1.5 | Upgrade |
Other Financing Activities | 40.32 | - | - | -12.28 | -2.41 | -20.41 | Upgrade |
Financing Cash Flow | 92.42 | 85.1 | -145.22 | 458.47 | -48.41 | -31.91 | Upgrade |
Foreign Exchange Rate Adjustments | 0 | 0 | -0.03 | 0.16 | -0.24 | -0.17 | Upgrade |
Net Cash Flow | 72.41 | 53.41 | -105.41 | 276.98 | 1.23 | 15.6 | Upgrade |
Free Cash Flow | 51.26 | 28.69 | -50.04 | 38.8 | 49.36 | 47.36 | Upgrade |
Free Cash Flow Growth | - | - | - | -21.41% | 4.24% | -51.90% | Upgrade |
Free Cash Flow Margin | 6.21% | 3.53% | -6.37% | 5.61% | 7.26% | 7.47% | Upgrade |
Free Cash Flow Per Share | 0.51 | 0.28 | -0.49 | 0.46 | 0.63 | 0.65 | Upgrade |
Cash Interest Paid | 0.68 | - | - | - | - | 0.08 | Upgrade |
Cash Income Tax Paid | 75.19 | 80.87 | 84.86 | 58.93 | 79.2 | 70.39 | Upgrade |
Levered Free Cash Flow | - | 27.34 | -68.83 | 41.25 | 21.46 | 11.86 | Upgrade |
Unlevered Free Cash Flow | - | 28.85 | -68.83 | 41.25 | 21.46 | 11.89 | Upgrade |
Change in Working Capital | -37.33 | -37.33 | -40.9 | -42.73 | -50.23 | -63.64 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.